Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?
Daniel E. Singer(Massachusetts General Hospital), Alan S. Go(Kaiser Permanente), Niela K. Pomernacki(Kaiser Permanente), Yuchiao Chang(Harvard University), Margaret C. Fang(San Francisco General Hospital), Natalia Udaltsova(Kaiser Permanente), Leila H. Borowsky(Massachusetts General Hospital)
Cited by 106
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
Heart Disease and Stroke Statistics—2013 Update
|Circulation|2012|5.2k